Bone Health: Why AuthAnnie Started Here

The Problem

Drugs like Evenity (romosozumab), Prolia (denosumab), and Tymlos (abaloparatide) represent critical advances in osteoporosis treatment. They are recommended by the American Society for Bone and Mineral Research (ASBMR), the National Osteoporosis Foundation (NOF), and the Endocrine Society for patients at high fracture risk.

Yet insurance companies routinely deny these treatments. Common denial reasons include:

• CO-4: “The procedure code is inconsistent with the modifier used or a required modifier is missing.”
• CO-16: “Claim/service lacks information or has submission/billing error(s).”
• PR-204: “This service/equipment/drug is not covered under the patient's current benefit plan.”

For practices specializing in bone health, these denials represent a significant burden — both financially and in terms of patient outcomes. Every delayed treatment means continued fracture risk for patients who have already been identified as high-risk.

A Typical Scenario

Margaret Chen is a fictional patient representing a composite of common clinical scenarios in osteoporosis care.

How AuthAnnie Responds

When a denial like Margaret's comes in, AuthAnnie:

1. Extracts clinical data — T-scores, FRAX risk scores, prior treatment history, relevant lab values, and the specific denial reason code.
2. Matches clinical guidelines — Identifies that ASBMR 2020 guidelines recommend romosozumab for postmenopausal women with T-score ≤ -2.5 and prior bisphosphonate use with continued fracture risk (per Camacho et al., Endocrine Practice, 2020).
3. Generates a tailored appeal — Produces a letter that addresses the specific denial reason, cites the relevant guidelines, and presents Margaret's clinical evidence in the format payers expect.

Why Bone Health Is the Perfect Starting Point

Bone health denials share characteristics that make them ideal for intelligent denial management:

• Clear clinical criteria — T-scores, FRAX scores, and prior therapy are objective, measurable data points.
• Well-defined guidelines — ASBMR, NOF, Endocrine Society, and ACR all publish clear treatment recommendations.
• High denial rates — Specialty biologics face disproportionately high prior authorization and denial rates.
• Significant patient impact — Delayed osteoporosis treatment directly increases fracture risk, with fractures carrying substantial morbidity and mortality in elderly patients.

Beyond Bone Health

While AuthAnnie started with bone health, the same approach applies across specialties. Any clinical scenario with objective data, clear guidelines, and payer resistance is a fit — rheumatology, oncology, neurology, cardiology, and more.

The platform is specialty-agnostic by design. Bone health is the proof of concept. The same clinical intelligence engine that fights an Evenity denial can fight a denial for any treatment where the evidence supports the prescription.